Xencor, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022
February 23, 2023 at 04:27 pm EST
Share
Xencor, Inc. reported earnings results for the fourth quarter and full year ended December 31, 2022. For the fourth quarter, the company reported sales was USD 21.61 million compared to USD 154.02 million a year ago. Net loss was USD 12.04 million compared to net income of USD 73.06 million a year ago. Basic loss per share from continuing operations was USD 0.2 compared to basic earnings per share from continuing operations of USD 1.25 a year ago. Diluted loss per share from continuing operations was USD 0.2 compared to diluted earnings per share from continuing operations of USD 1.21 a year ago.
For the full year, sales was USD 164.58 million compared to USD 275.11 million a year ago. Net loss was USD 55.18 million compared to net income of USD 82.63 million a year ago. Basic loss per share from continuing operations was USD 0.93 compared to basic earnings per share from continuing operations of USD 1.42 a year ago. Diluted loss per share from continuing operations was USD 0.93 compared to diluted earnings per share from continuing operations of USD 1.37 a year ago.
Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases. More than 20 candidates engineered with its XmAb technology are in clinical development, and three XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly owned development candidates include Vudalimab, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, and Novartis XmAb undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of fbalropendekin alfa (XmAb306/RG6323), XmAb564, and XmAb662. Its other clinical-stage drug candidates consist of Obexelimab, AIMab7195 (XmAb7195), and Xpro1595. Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.
XENCOR, INC. 
